Table I.
Demographic, clinical and laboratory data of the study population.
| Variable | Patients survived | Patients died | p |
|---|---|---|---|
| ADHF episodes, n (%) | 1487 (87.3) | 217 (12.7) | |
| Sex, n (%) | 0.310 | ||
| Men | 712 (47.9) | 112 (51.6) | |
| Women | 775 (52.1) | 105 (48.4) | |
| Age (years) | 83 (76–88) | 87 (80–92) | 0.001 |
| Clinical history | |||
| Ischemic heart disease | 410 (27.6) | 53 (24.3) | 0.353 |
| Hypertensive cardiomyopathy | 1167 (78.5) | 154 (70.9) | 0.019 |
| Atrial fibrillation | 666 (44.8) | 101 (46.8) | 0.598 |
| Valvular heart disease | 300 (20.2) | 39 (18.2) | 0.574 |
| Chronic renal failure | 280 (18.8) | 47 (21.7) | 0.340 |
| Pacemaker | 232 (15.6) | 41 (18.7) | 0.260 |
| Drugs | |||
| Loop diuretics | 868 (58.4) | 131 (60.3) | 0.641 |
| Potassium-sparing diuretics | 247 (16.6) | 37 (17.0) | 0.918 |
| Beta-Blockers | 671 (45.1) | 79 (36.6) | 0.031 |
| ACE inhibitors/sartans | 578 (38.9) | 64 (29.4) | 0.011 |
| Laboratory data | |||
| Hb (g/L) | 124 (110–138) | 119 (105–134) | 0.002 |
| Creatinine (mmol/L) | 101 (81–134) | 120 (89–172) | 0.000 |
| Sodium (mol/L) | 136 (135–138) | 138 (134–142) | 0.035 |
| Chloride (mol/L) | 99 (96–102) | 97 (93–101) | 0.000 |
| Potassium (mol/L) | 4.3 (4.1–5.2) | 4.4 (3.9–5.1) | 0.122 |
| Leukocytes (x109/L) | 9.1 (7.1–11.6) | 9.2 (6.7–13.2) | 0.516 |
| BNP (pg/mL) | 7517 (3031–13504) | 11743 (6347–18376) | 0.000 |
| RDW (%) | 14.3 (13.4–15.6) | 15.2 (14.2–16.6) | 0.000 |
ACE, angiotensin converting enzyme; BNP, B-type natriuretic peptide; RDW, red blood cell distribution width.